Empresas›PTN

PTN · PALATIN TECHNOLOGIES INC

preparados farmacéuticos · CIK 0000911216

PALATIN TECHNOLOGIES INC (PTN) cotiza en el NASDAQ y se dedica a preparados farmacéuticos. Aquí están 49 documentos que ha presentado ante la SEC, desde 10 sep 2025. En sus informes aparecen frases que este sitio vigila: duda sustancial sobre la continuidad de la empresa y contrasplit de acciones. Están citadas literalmente más abajo.

Aguanta

2,1 trimestres

7,5 M$ a 30 jun 2026 · gasta 3,5 M$/trimestre

Dilución

+4,5%

entre 12 nov 2025 y 12 may 2026

Sobre el capital

20,3%

en corto a 15 sep 2026, según FINRA

Último

28 sep 2026

Informe anual

En esta ficha (en gris, lo que todavía no tenemos): Caja · Ensayos · Acciones · Cortas · Directivos · Accionistas · Documentos

Caja

Lo que la empresa declara tener en caja en cada cierre, según su propio balance. A trazo discontinuo, sumando las inversiones a corto plazo, que es lo que divide los trimestres de arriba.

Ensayos clínicos

11 ensayos registrados en clinicaltrials.gov: 2 en marcha (reclutando, o con los pacientes que ya entraron en seguimiento) y 9 cerrados. Cada uno tiene su ficha aquí, en castellano. Qué significa cada estado.

Superar una fase no apaga la anterior: es normal ver el mismo fármaco en dos ensayos a la vez, cada uno en la suya, mientras el de antes sigue con los pacientes que ya entraron y no admite nuevos. La fecha de lectura marcada como prevista es una estimación del promotor, no un compromiso: se mueve, y moverse es a veces la noticia. Las marcadas como real ya han ocurrido.

Acciones en circulación

Cuántas acciones existen de esta empresa, según lo que ella misma declara en cada informe. Cada acción nueva reparte el mismo negocio entre más dueños: si la curva sube y tú no compras más, tu parte baja. Una biotecnológica sin ingresos casi solo puede financiarse emitiendo, así que subir no es por sí mismo una mala noticia — lo que se mira es cuánto y cuando. Qué significa cada documento.

Posiciones cortas declaradas a FINRA

Qué es vender en corto. Lo que los miembros de FINRA declaran cada quincena sobre esta empresa. FINRA lo publica al septimo día hábil tras cada liquidación y el fichero llega aquí unos días después: lo que ves tiene entre dos y cuatro semanas, según cuando entro y cuánto falta para el siguiente. Aquí se publica el dato; no se interpreta.

Acciones cortas

0,4

M de acciones · 15 sep 2026

Sobre el capital

20,3%

de 1,8 M de acciones en circulación a 12 may 2026

Variación

+15.725

acciones frente a la quincena anterior declarada

Días para cubrir

1,6

al volumen medio declarado

El porcentaje es sobre las acciones en circulación, que no es lo mismo que el capital flotante: el flotante descuenta lo que tienen iniciados y accionistas restringidos, así que siempre es menor y el porcentaje sobre el sería mayor. No lo publicamos porque la SEC solo da el flotante en dólares y una vez al año, y pasarlo a acciones pediría el precio de ese día.

Fuente: el fichero de FINRA de esa quincena, que es lo que se lee aquí, donde esa quincena figura como PTN.

Qué hacen sus directivos con sus acciones

Compras y ventas a precio de mercado, declaradas en el formulario 4 de la SEC. No salen las concesiones de acciones, los ejercicios de opciones ni las entregas para pagar impuestos: son retribución, no una opinión sobre la empresa. El cargo va como lo escribe el formulario, en inglés; cuando no lo declara ponemos el papel en castellano.

La marca PLAN 10B5-1 es del propio formulario: dice que la operación venia de un plan escrito de antemano, a fechas fijas. Solo se marca cuando el declarante lo declara; que no aparezca no significa que no lo hubiera.

Quién tiene más del 5%

Lo declara el propio accionista ante la SEC al cruzar ese umbral, y después cada vez que su posición cambia de forma significativa. De cada grupo, su última declaración. Solo desde diciembre de 2024: es cuando la SEC hizo obligatorio presentar estas declaraciones en formato estructurado. Las anteriores son documentos de texto libre y no se leen aquí, así que un accionista que declaro antes y no ha vuelto a hacerlo NO sale. ⚠️ Y cada declarante calcula su porcentaje a su manera —unos sobre las acciones en circulación y otros añadiendo los derechos que podrían ejercer—, así que dos cifras de la misma empresa no son estrictamente comparables.

Han bajado del 5%

Su última declaración ya queda por debajo del umbral: es la de salida, y después no tienen obligación de volver a declarar.

Un — en el porcentaje significa que el documento no trae una cifra que se pueda leer —a veces remite a la portada en texto libre—, nunca «cero»; en Acciones, que el declarante no puso el número; y en Quién declara, que en vez de un nombre escribió un párrafo entero del formulario y preferimos no publicarlo antes que publicar eso como si fuera un nombre.

El sector se mira también en conjunto, en las herramientas: el radar de dilución ordena por los trimestres de caja que quedan, el ranking de posiciones cortas por días para cubrir, las operaciones de directivos por fecha, los accionistas de más del 5% por lo que declaran, y el calendario por la fecha que cada promotor estima para su siguiente lectura. Son listas del sector: sale quien tiene ese dato declarado. Piden cuenta.

Documentos presentados ante la SEC49

Se enseñan los 40 más recientes.

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

2026

1. 28 sep 202610-KInforme anualEDGAR

   La empresa señala que su historial de pérdidas operativas y su necesidad de más financiación han llevado a la dirección a concluir que existe una duda sustancial sobre su capacidad para continuar como empresa en funcionamiento.

   Lo que dice el documentoour history of operating losses and our need to obtain additional financing have caused management to conclude that there is substantial doubt regarding our ability to continue as a going concern

   Traducción automática (claude-sonnet-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

   La empresa hizo una consolidación de acciones de 1 por 50 con efecto el 8 de agosto de 2025 y sus acciones volvieron a cotizar en NYSE American el 12 de noviembre de 2025.

   Lo que dice el documentowe effected a 1-for-50 reverse stock split effective August 8, 2025, and our common stock resumed trading on NYSE American on November 12, 2025. On May 29, 2026, we voluntarily transferred the listing of our common stock to the Nasdaq Capital Market, which requires, among other things, a minimum bid price of $1.00 per share, stockholders’ equity of at least $2.5 million and a minimum market value of publicly held shares.

   Traducción automática (claude-sonnet-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

   Frente al informe anterior del mismo tipo: 872 frases nuevas y 892 eliminadas. (ver el anterior)

   Ver 12 de las 872 frases nuevas

   Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $.01 per share PTN Nasdaq Capital Market Securities registered pursuant to Section 12(g) of the Act:

   Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

   Yes ☐ No ☒ State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter (December 31, 2025): $25,695,597 Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date (September 25, 2026): 1,780,939 PALATIN TECHNOLOGIES, INC.

   Form 10-K Summary 83 Special Note Regarding Forward-Looking Statements In this Annual Report on Form 10-K (this “Annual Report”) references to “we,” “our,” “us,” the “Company” or “Palatin” means Palatin Technologies, Inc. and its subsidiary.

   Investors are cautioned that statements that are not strictly historical facts contained in this Annual Report, including, without limitation, the following are forward-looking statements: ● our history of operating losses and our need to obtain additional financing have caused management to conclude that there is substantial doubt regarding our ability to continue as a going concern; ● our ability to obtain additional financing on terms acceptable to us, or at all, including unavailability of funds or delays in receiving funds as a result of economic disruptions; ● our expectation that we will incur losses for the foreseeable future and may never achieve or maintain profitability; ● our business, financial condition, and results of operations may be adversely affected by increases in costs of and delays in conducting human clinical trials and the performance of our contractors and suppliers, reduction in our productivity or the productivity of our contractors and suppliers, supply chain constraints, and labor shortages; ● whether Boehringer Ingelheim International GmbH (“Boehringer Ingelheim”), which in August 2025 acquired certain Palatin intellectual property to first-in-class melanocortin receptor-targeted compounds developed by Palatin, will be able to successfully develop a product for the treatment of retinal diseases; ● the results of further development, clinical trials and the timing of regulatory submissions with our obesity program, including a novel once-weekly peptide melanocortin receptor-4 (“MC4R”) selective agonist with a Phase 1 clinical study projected in the first half of calendar year 2027 and an oral small molecule MC4R selective agonist with a Phase 1 clinical study projected in the second half of calendar year 2027;

   PL8177, an oral peptide melanocortin receptor-1 (“MC1R”) formulation for treatment of ulcerative colitis, which reported positive topline data in a Phase 2 clinical trial proof-of-concept trial in the first quarter of 2025; and a melanocortin receptor agonist for diabetic nephropathy, which reported positive topline data in the fourth quarter of 2024; ● estimates of our expenses, future revenue and capital requirements; ● our ability to achieve profitability; ● our ability to advance product candidates into, and successfully complete, clinical trials; ● the initiation, timing, progress and results of future preclinical studies and clinical trials, and our research and development programs; ● the timing or likelihood of regulatory filings and approvals; ● our expectations regarding the clinical efficacy and utility of our melanocortin agonist product candidates for treatment of inflammatory and autoimmune related diseases and disorders, including ocular indications; ● our ability to compete with other products and technologies treating the same or similar indications as our product candidates; ● the ability of our contract manufacturers to perform their manufacturing activities for us in compliance with applicable regulations; ● our ability to recognize the potential value of our licensing arrangements with third parties; i ● the potential to achieve revenues from the sale of our product candidates; ● our ability to obtain adequate reimbursement from private insurers and other healthcare payers; ● our ability to maintain product liability insurance at a reasonable cost or in sufficient amounts, if at all; ● the performance and retention of our management team, senior staff professionals, other employees, and third-party contractors and consultants; ● the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology in the United States and throughout the world; ● our compliance with federal and state laws and regulations; ● the timing and costs associated with obtaining regulatory approval for our product candidates; ● the impact of fluctuations in foreign exchange rates; ● the impact of any geopolitical instability, economic uncertainty, financial markets volatility, or capital markets disruption resulting from the ongoing military conflict between Russia and Ukraine, and any resulting effects on our revenue, financial condition, or results of operations; ● the impact of legislative or regulatory healthcare reforms in the United States; ● our ability to adapt to changes in global economic conditions as well as competing products and technologies; and ● our ability to remain listed and our shares traded on the Nasdaq stock exchange.

   Discussion of the risks listed below, and other risks that we face, are discussed in the section titled “Risk Factors” in Part I, Item 1A of this Annual Report.

   Risks Related to Our Financial Results and Need for Financing ● Our management has determined that there is substantial doubt about our ability to continue as a going concern, which may make it more difficult and more expensive for us to raise capital. ● We have a history of substantial net losses, including a net loss of $8.4 million for the year ended June 30, 2026, and expect to incur substantial net losses over the next few years, and we may never achieve or maintain profitability. ● We will need additional funding, including funding to complete clinical trials for our product candidates, which additional funding may not be available on acceptable terms, if at all. ● We have a limited operating history upon which to base an investment decision. ● Raising additional capital may cause dilution to existing stockholders, restrict our operations or require us to relinquish rights. ii Risks Related to Our Business, Strategy, and Industry ● Our product candidates, including a novel once-weekly peptide MC4R agonist, an oral small molecule MC4R agonist, and MC1R agonist PL8177 for the treatment of ulcerative colitis, are still in the early stages of development and remain subject to clinical testing and regulatory approval.

   If we are unable to successfully develop and test our product candidates, we will not be successful. ● If clinical trials for our product candidates are prolonged or delayed, we may be unable to commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any revenue from potential product sales. ● Even if our product candidates receive regulatory approval in the United States, they may never achieve market acceptance in the United States or approval outside the United States, in which case our business, financial condition and results of operations will be materially adversely affected. ● If side effects emerge that can be linked to any of our product candidates (either while they are in development or after they are approved and on the market), we may be required to perform lengthy additional clinical trials, change the labeling of any such products, or withdraw such products from the market, any of which would hinder or preclude our ability to generate revenues. ● Palatin’s MC4R candidates, if approved, would enter markets in which an established MC4R therapy may already have significant physician experience, reimbursement coverage and patient adoption, including the possibility that Rhythm Pharmaceuticals’ next-generation products could reach the market before Palatin’s candidates. ● Our collaborations with third parties may not be successful, and we may not realize the anticipated benefits from these arrangements.

   Risks Related to Government Regulation ● Both before and after marketing approval, our product candidates are subject to ongoing regulatory requirements and, if we fail to comply with these continuing requirements, we could be subject to a variety of sanctions, and the sale of any approved commercial products could be suspended.

   Risks Related to the Ownership of Our Common Stock ● Our stock price is volatile and may fluctuate in a way that is disproportionate to our operating performance, and we expect it to remain volatile, which could limit investors’ ability to sell stock at a profit. ● Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be our stockholders’ sole source of gains. ● As of September 25, 2026, there were 8,763,962 shares of common stock underlying outstanding convertible preferred stock, options, restricted stock units and warrants.

   Stockholders may experience dilution from the conversion of preferred stock, exercise of outstanding options and warrants and vesting and delivery of restricted stock units. ● Our common stock was delisted from NYSE American in 2025 and traded over the counter for six months; if we fail to satisfy the continued listing requirements of the Nasdaq Capital Market, our common stock could again be delisted. iii PART I Item 1.

2. 14 ago 2026SC 13G/ACambio en participación significativaEDGAR
3. 5 ago 20264Operación de un directivo o accionista significativoEDGAR

   No declara compras, ventas ni otras operaciones con acciones; lo que declare, en el documento original.

4. 5 ago 20264Operación de un directivo o accionista significativoEDGAR

   No declara compras, ventas ni otras operaciones con acciones; lo que declare, en el documento original.

5. 5 ago 20264Operación de un directivo o accionista significativoEDGAR

   No declara compras, ventas ni otras operaciones con acciones; lo que declare, en el documento original.

6. 3 ago 20268-KHecho relevanteEDGAR
7. 17 jul 20264Operación de un directivo o accionista significativoEDGAR

   Wills Stephen T (directivo):

   • acciones entregadas para pagar impuestos, 22 acciones a 11,77 $ · de un plan 10b5-1 escrito de antemano.
   • acciones entregadas para pagar impuestos, 79 acciones a 11,72 $ · de un plan 10b5-1 escrito de antemano.
   • acciones entregadas para pagar impuestos, 94 acciones a 14,34 $ · de un plan 10b5-1 escrito de antemano.
   • Ninguna es una compra ni una venta en bolsa.
8. 17 jul 20264Operación de un directivo o accionista significativoEDGAR

   Spana Carl (presidente y consejero delegado):

   • acciones entregadas para pagar impuestos, 33 acciones a 11,77 $ · de un plan 10b5-1 escrito de antemano.
   • acciones entregadas para pagar impuestos, 119 acciones a 11,72 $ · de un plan 10b5-1 escrito de antemano.
   • acciones entregadas para pagar impuestos, 142 acciones a 14,34 $ · de un plan 10b5-1 escrito de antemano.
   • Ninguna es una compra ni una venta en bolsa.
9. 25 jun 2026DEF 14AConvocatoria de junta de accionistasEDGAR
10. 28 may 2026CERTCertificación de admisión a cotizaciónEDGAR